Skip to content
All resources

Testing, quality and handling

Compounded Peptides in Canada: How Compounding Differs From Research Peptides

AR

By

· 9 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 8 sections
  1. What is pharmacy compounding?
  2. Who regulates compounding in Canada?
  3. When does compounding become manufacturing?
  4. What has Health Canada said about compounded peptides?
  5. How is a compounded preparation different from a research reagent and an authorised drug?
  6. What does the published evidence say about compounded peptide quality?
  7. What this page does not cover
  8. Frequently asked questions

In Canada, a compounded peptide is a medication that a pharmacist or other licensed practitioner prepares for one patient, within a patient-practitioner relationship, usually on a prescription. Provincial and territorial regulators oversee it. It is neither an authorised drug with a DIN nor a research reagent. Health Canada expects compounded drugs to be made from authorised drugs or recognised ingredients. It has said that peptide activities involving unauthorized ingredients may count as manufacturing, which brings them under federal law.

A compounding pharmacy bench with a mortar and pestle, balance and amber bottles beside a research bench with sealed vials and a pipette
Illustration: pharmacy compounding and laboratory research supply are different routes.

What is pharmacy compounding?

Health Canada's peptides regulations page describes compounding as "the process of combining, mixing or altering ingredients to prepare a medication for a patient's specific medical needs." Its example is a pharmacist preparing a liquid version of a medicine for a child who cannot swallow tablets. Compounding is a recognised part of health care practice and falls mainly under provincial and territorial rules.

The federal framework is Health Canada's Policy on Manufacturing and Compounding Drug Products in Canada (POL-0051), issued in 2009. It says compounding is practised mainly by pharmacists and regulated by each province or territory, while drug manufacturing is regulated federally under the Food and Drugs Act. Its first guiding principle is that compounding "must not be used as a means to bypass the federal drug review and approval system."

Who regulates compounding in Canada?

The provincial and territorial regulatory bodies regulate it. For pharmacists, that means the college or pharmacy regulator in each province. POL-0051 lists them all, from the College of Pharmacists of British Columbia to the Ordre des pharmaciens du Québec and the Nova Scotia College of Pharmacists. The National Association of Pharmacy Regulatory Authorities (NAPRA) publishes national model standards for pharmacy practice and compounding, which provincial regulators can adopt or adapt. Which standard applies, and in what version, depends on the province, so check the provincial regulator's own publications.

Health Canada steps in when an activity stops being compounding. POL-0051 says that where a provincial regulator decides an activity falls outside its jurisdiction, "the activity is likely to be manufacturing". The parties involved then have to follow the federal approval process, which means a DIN, an establishment licence and good manufacturing practices.

When does compounding become manufacturing?

POL-0051 gives a set of questions. Health Canada weighs them together, case by case.

QuestionPoints to compoundingPoints to manufacturing
Is there a demonstrated patient-practitioner relationship?YesNo
Is the product resold by a third party outside that relationship?NoYes
Is the activity regulated, and the facility inspectable, by the province?YesNo
Is an identical product commercially available?NoYes
Is the product or service advertised to the general public?NoYes
Is the amount made inordinate, or made routinely?NoYes

The policy also covers ingredients. A compounded product "should be produced from an authorized drug or Active Pharmaceutical Ingredient (API) used in an authorized drug for use in Canada or listed in a recognized Pharmacopoeia." Health Canada's 2026 peptides page repeats the point: compounded drugs are expected to be prepared from an authorised drug, an ingredient used in an authorised drug, or an ingredient listed in a recognised pharmacopoeia such as the BP, USP or Ph. Eur. Sterile compounding is limited to settings with documented clean-room standards. Compounding pharmacists are responsible for the safety, efficacy and quality of what they make, and must not advertise specific compounded products to the public.

What has Health Canada said about compounded peptides?

The October 2026 peptides page addresses compounded peptides directly. Health Canada says it is "aware of peptides being compounded in Canada" and is working with provincial and territorial regulators. It says "activities involving unauthorized peptide ingredients, or those that extend beyond the accepted scope of compounding, may be considered manufacturing rather than compounding," and that it will act under the Food and Drugs Act in those cases.

Two recalls show this in practice. In January 2025, a Calgary compounding pharmacy recalled a semaglutide and pyridoxine preparation because it "was produced with an unauthorized active pharmaceutical ingredient." In May 2026, a British Columbia supplier recalled BPC-157 and GHK-Cu powders sold to compounding and community pharmacies. Health Canada classed them as unauthorized active pharmaceutical ingredients and listed the recall as Type I. Both notices are in Health Canada's recalls and safety alerts database (recalls-rappels.canada.ca). In both cases, using the ingredient in a pharmacy did not make it authorised.

How is a compounded preparation different from a research reagent and an authorised drug?

These are three separate things, and each comes with a different set of assurances.

Authorised drugCompounded preparationResearch reagent
Who it is forPatients, for the authorised usesOne patient, for a specific medical needA laboratory; not for people
Who oversees itHealth Canada (DIN, Notice of Compliance, establishment licence, GMP)Provincial regulator; federal law still appliesNo pre-market review; subject to the Food and Drugs Act
What the ingredient must beMade to the filed specificationAn authorised drug or API, or a pharmacopoeial ingredientNo required standard
Evidence of efficacy reviewedYesNo, the product is not assessedNo
Requires a prescriptionIf on the Prescription Drug ListUsually prepared on a prescriptionNot applicable; not for human use

A compounded preparation is not a cheaper copy of the authorised drug. POL-0051 says compounding should not duplicate an approved product that is commercially available, except during a shortage. Health Canada's peptides page says a compounded drug "is not subject to the same Health Canada assessment and authorization process" as a manufactured one.

A research reagent is not a compounded drug either. It is supplied as a laboratory chemical, with no patient, no prescription and no practitioner involved. Its quality evidence is whatever the analytical documents for that lot show, as what a certificate of analysis establishes explains. Health Canada's position is that a research label does not make a product legal to import or sell, a point covered in research use only: what the label means. How Health Canada regulates drugs sets out the authorised-drug side, and generic semaglutide in Canada explains why a product described as "generic" still needs its own authorisation.

What does the published evidence say about compounded peptide quality?

Most of the published data is American, but the risks are the same wherever compounding happens. A 2013 review notes that compounded drugs are exempt from good manufacturing practice, are not clinically evaluated, and fail specification testing more often than approved drugs. It recommends limiting compounding to patients who need something not commercially available (PMID 23526368). The worst case on record is the 2012 fungal meningitis outbreak in the United States, traced to contaminated methylprednisolone from a single compounding pharmacy. There were 749 reported cases in 20 states and 61 deaths (PMID 23252499).

For GLP-1 drugs, a review of US adverse event reports found that reports involving compounded products were more likely to mention preparation errors, contamination and manufacturing problems (PMID 40285721). Testing by researchers at Eli Lilly, which makes tirzepatide and so has a commercial interest, reported a previously unidentified impurity across compounded tirzepatide and vitamin B12 combination products. It formed from a reaction between the two (PMID 42010938). A 2026 article reviewed how a US federal advisory committee assessed synthetic peptides nominated for compounding (PMID 42752426).

The United States splits compounding into two categories, which are often mentioned in Canadian discussions. Section 503A of the US Federal Food, Drug, and Cosmetic Act covers traditional patient-specific pharmacy compounding. Section 503B, created by the Drug Quality and Security Act of 2013, covers outsourcing facilities that compound at scale under FDA oversight (PMID 42242462). Neither category exists in Canadian law. Canada uses the compounding-versus-manufacturing distinction in POL-0051 instead.

What this page does not cover

This page does not explain how to obtain a compounded product, and it does not say whether any compounded peptide is appropriate for anyone. Those are clinical decisions for a patient and a licensed practitioner. Whether a particular preparation is lawful turns on the questions in POL-0051 and on the provincial regulator's standards, and only those bodies can answer them. Health Canada's GLP-1 warnings covers the federal enforcement record. For the chemistry of the compounds themselves, see peptides explained.

Nothing here is medical, dosing, or therapeutic guidance, and nothing here is legal advice.

Frequently asked questions

Is compounding peptides legal in Canada? Compounding is a recognised, provincially regulated practice. Health Canada says peptide compounding must stay within the accepted scope of compounding and be prepared from authorised drugs, ingredients used in authorised drugs, or pharmacopoeial ingredients. Activities using unauthorized peptide ingredients may be treated as manufacturing and enforced under federal law.

Is a compounded peptide the same as the brand-name drug? No. A compounded preparation is not assessed or authorised by Health Canada the way a manufactured drug is. It has no DIN of its own. POL-0051 says compounding should not duplicate an approved product that is commercially available, except during a shortage.

Who do I contact about a compounding pharmacy in Canada? The pharmacy regulator in the province or territory where the pharmacy is located. POL-0051 lists them. Health Canada's Regulatory Operations and Enforcement Branch handles activities that may be manufacturing, and its health product complaint form is linked from the peptides regulations page.

Can a compounding pharmacy use a research-grade peptide? Health Canada expects compounded drugs to be prepared from an authorised drug, an ingredient used in an authorised drug sold in Canada, or an ingredient listed in a recognised pharmacopoeia. Its May 2026 Type I recall of BPC-157 and GHK-Cu powders supplied to pharmacies shows that it treats unauthorized ingredients in pharmacies as a recall matter.

What are 503A and 503B? They are sections of the US Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional patient-specific pharmacy compounding. Section 503B, added in 2013, created outsourcing facilities that compound at larger scale under FDA oversight. Neither applies in Canada, which relies on Health Canada's compounding-versus-manufacturing policy and provincial regulation.

Selected Research References

  1. Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs in R&D. 2013;13(1):1-8. pubmed.ncbi.nlm.nih.gov/23526368
  2. Smith RM, Schaefer MK, Kainer MA, et al. Fungal infections associated with contaminated methylprednisolone injections. New England Journal of Medicine. 2013;369(17):1598-1609. pubmed.ncbi.nlm.nih.gov/23252499
  3. McCall KL, Mastro Dwyer KA, Casey RT, et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opinion on Drug Safety. 2026;25(3):581-588. pubmed.ncbi.nlm.nih.gov/40285721
  4. Jordan B, Arbogast L, Clemens M, et al. A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications. Expert Opinion on Drug Safety. 2026;25(5):837-845. pubmed.ncbi.nlm.nih.gov/42010938
  5. Willis J, Vu N. Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards. International Journal of Pharmaceutical Compounding. 2026;30(4):329-336. pubmed.ncbi.nlm.nih.gov/42752426
  6. McCall KL, Lynch SE, Hageman EA, Williams KG. A quantitative and qualitative study of US FDA inspection reports of 503B outsourcing facilities. Journal of the American Pharmacists Association. 2026;66(5):103156. pubmed.ncbi.nlm.nih.gov/42242462

All products sold by NovaEvum, a Canadian research peptide supplier, are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.